文献速递脑血管病外科神经重症

血流导向装置在急性破裂脑动脉瘤早期治疗中的应用

Flow-diverter stents in the early management of acutely ruptured brain aneurysms: effective rebleeding protection with low thromboembolic complications.
PubMed 文献 · J Neurosurg · 2021-04-16

该回顾性研究纳入76例急性破裂动脉瘤伴蛛网膜下腔出血患者,在诊断后4天内植入血流导向装置,采用抗血小板方案及围手术期管理。结果显示无目标动脉瘤再出血,81.6%患者90天mRS 0-2分,3-6个月随访完全或近完全闭塞率95.5%。

要点

  • 血流导向装置治疗急性破裂动脉瘤可有效防止再出血
  • 围手术期采用阿司匹林和氯吡格雷抗血小板及血小板检测
  • 即时完全闭塞率低但延迟闭塞率高,临床预后良好

核心结论

  • 血流导向装置是治疗部分急性破裂动脉瘤的有效策略,尽管即时闭塞率低,但能提供重要的防再出血保护。

研究设计与样本

  • 回顾性研究,纳入2010年7月至2018年9月间76例急性破裂动脉瘤伴SAH患者,均在诊断后4天内接受血流导向装置作为单一治疗。

主要发现

  • 76例患者中女性占61%,平均年龄42.8±11.3岁,装置植入中位时间为诊断后2天。
  • 操作相关临床并发症6例(7.9%),其中2例(2.6%)导致永久性神经功能障碍。
  • 即时完全闭塞11例(14.5%),持续充盈65例(85.5%),但无目标动脉瘤再出血。
  • 90天mRS 0-2分(优良临床结局)62例(81.6%)。
  • 3-6个月血管造影随访中,64/67例(95.5%)达到完全或近完全闭塞;12个月评估病例均闭塞。

临床怎么用

  • 对于部分急性破裂动脉瘤,可考虑使用血流导向装置,但需严格选择患者并遵循抗血小板方案。
  • 术前放置脑室外引流阈值低,支架植入前使用阿司匹林和氯吡格雷并进行血小板检测。

局限性

  • 回顾性研究,样本量有限,缺乏对照组,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Flow-diverter stents (FDSs) are not generally used for the management of acutely ruptured aneurysms with associated subarachnoid hemorrhage (SAH). Herein, the authors present their experience with FDSs in this scenario, focusing on the antiplatelet regimen, perioperative management, and outcome. METHODS: The authors retrospectively reviewed their institutional database for the treatment and outcomes of all patients with acutely ruptured aneurysms and associated SAH from July 2010 to September 2018 who had received an FDS implant as stand-alone treatment within 4 days after diagnosis. The protocol with the use of flow diversion in these patients includes a low threshold for placement of external ventricular drains before stenting, followed by the administration of aspirin and clopidogrel with platelet testing before stent implantation. With this approach, the risk of hemorrhage and stent-related thrombus formation is limited. Demographic, clinical, technical, and imaging data were analyzed. RESULTS: Overall, 76 patients (61% females, mean age 42.8 ± 11.3 years) met the inclusion criteria. FDS implantation was performed a median of 2 days after diagnosis. On average, 1.05 devices were used per procedure. There was no procedural mortality directly attributed to the endovascular intervention. Procedural device-related clinical complications were recorded in a total of 6 cases (7.9%) and resulted in permanent neurological morbidity in 2 cases (2.6%). There was complete immediate aneurysm occlusion in 11 patients (14.5%), and persistent aneurysm filling was seen in 65 patients (85.5%). Despite this, no patient presented with rebleeding from the target aneurysm. There was an excellent clinical outcome in 62 patients (81.6%), who had a 90-day modified Rankin Scale score of 0-2. Among the 71 survivors, total or near-total occlusion was observed in 64/67 patients (95.5%) with a 3- to 6-month angiographic follow-up and in all cases evaluated at 12 months. Five patients (6.6%) died during follow-up for reasons unrelated to the procedure or new hemorrhage. CONCLUSIONS: Flow diversion is an effective therapeutic strategy for the management of select acutely ruptured aneurysms. Despite low rates of immediate aneurysm occlusion after FDS implantation, the device exerts an important protective effect. The authors' experience confirmed no aneurysm rerupture, high rates of delayed complete occlusion, and complication rates that compare favorably with the rates obtained using other techniques.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Cohen JE, Gomori JM, Moscovici S, et al. Flow-diverter stents in the early management of acutely ruptured brain aneurysms: effective rebleeding protection with low thromboembolic complications. J Neurosurg. 2021. PMID: 33862594. doi:10.3171/2020.10.JNS201642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。